-
Home
-
-
-
-
-
-
-
-
-
WHO WE ARE |
The Canadian Association of Nuclear Medicine strives for excellence in the practice of diagnostic and therapeutic nuclear medicine by promoting the continued professional competence of nuclear medicine specialists, establishing guidelines of clinical practice, and encouraging biomedical research. We work with all professionals in nuclear medicine to ensure that Canadians have access to the highest quality nuclear medicine services.
|
LATEST UPDATES | Isologic launches Illuccix® PSMA PET Imaging Agent to Detect Prostate Cancer: Read press release HERE | The new AMSMNQ'swebsite is now online and accessible to the public. |
BECOME A MEMBER | CANM ANNUAL CONFERENCE 2023 The CANM is proud to announce our annual conference in 2023 will be held in Ottawa, Ontario Dates: From October 19 - 21 2023 At the Brookstreet Hotel More information to come. Stay tuned |
EDUCATION
| Therapeutic Radiopharmaceuticals A presentation by Dr. Svetlana Selavinova on Therapeutic Radiopharmaceuticals... | PET TRACERS Dr Jan Andersson shares an overview of general PET radiopharmaceutical theory and production... | SPECT TRACERS 2 Dr Mihaela Ginj reviews the non-Tc99m SPECT radiopharmaceuticals available on the Canadian market... Watch |
AI auto-contouring solution, Contour ProtégéAI™ (by MIM Software Inc.)
MIM Software Inc., a leading global provider of medical imaging software, announced today it has received approval from Health Canada for its AI auto-contouring solution, Contour ProtégéAI 2022 - 11 - 01
Telix's Illuccix, a kit for 68Ga-PSMA-11 injection
ealth Canada has approved Illuccix, a kit for the preparation of gallium-68 (68Ga) gozetotide (also known as PSMA-11) injection, a radioactive diagnostic agent indicated for positron emission tomography (PET) of PSMA-positive lesions in patients with prostate cancer.1,2 2022 - 10 - 18 |